ClinicalTrials.gg
RecruitingNCT02548546Updated Sep 24, 2026

Estimation of Biomechanical Aortic Wall Properties in Healthy and Aneurysmal Aortas Using Novel Imaging Techniques

An interventional study of ECHO and ECG-gated MRA in Abdominal Aortic Aneurysm, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 122 studies in Aortic Aneurysm, Abdominal with a site in United States — 28 open to participants now, 35 under way, 1 of them phase 3. Aortic Aneurysm, Abdominal · United States.

Planned enrollment
60th of 85
30 · median 94
Started
2015
with 6 others
No phase
64 of 122
14 open now
Primary completion
2028-08
later than 21 of 34 live
Registered
74th of 122
by date
Lead sponsor
4 of 122
Mayo Clinic

Among the 122 studies in Aortic Aneurysm, Abdominal with a site in United States, this one is the 60th largest by planned enrollment of the 85 interventional ones, is one of 7 that started in 2015, is one of 64 with no phase, reaches primary completion later than 21 of the 34 other live ones, and was the 74th registered.

By phase

122 studies; the count open now beside each. This study's row is marked.

No phasethis study64 · 14 open
Observational32 · 9 open
Phase 18 · 2 open
Phase 26 · 1 open
Other kind5 · 0 open
Phase 44 · 1 open
Phase 1/21 · 0 open
Phase 2/31 · 1 open
Phase 31 · 0 open

By the year they started

First in 1998; this study’s year is marked. 7 started in 2015.

Size and results

Median enrollment 94 across the 85 interventional studies, 210 across the 32 observational. Of the 73 that completed or were terminated, 39 (53%) have results posted.

Was this useful?
Watch this landscapeDownload CSVWith an account: a weekly mail of what changed among 122 studies in Aortic Aneurysm, Abdominal with a site in United States, or all of them as a file.
02

Study summary

The primary aim of this study is to establish the practicality of using two novel imaging modalities for the assessment of biomechanical properties of the aorta.

Read the detailed description

Patients with Abdominal Aortic Aneurysm, (AAA), will be identified within the vascular surgery practice. Those patients who meet standard indications for surgery including symptomatic AAA, size >5.0-5.5 cm, or rapidly enlarging >0.5 cm per 6 months will have standard pre-operative work-up which includes magnetic resonance angiogram (MRA) and Echocardiogram (ECHO). These pre-operative studies will be modified for the study patients to include electrocardiogram(ECG)-gating (coupled with MR angiogram) and 2-Dimensional speckle-tracking ultrasound of the abdominal aorta. Patients in the study will be followed for 1 year. Measurements will be analyzed for any relationship between aortic wall properties and clinical outcomes such as aneurysm growth, rupture risk or aortic dissection. This study will be comparing 3 groups of patients: no surgery (surveillance), open surgery, and endovascular aneurysm repair (EVAR).

03

Conditions studied

  • Abdominal Aortic Aneurysm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients >18 years of age with ability to provide .
  • Patients with either symptomatic or asymptomatic AAA as defined by aortic diameter ≥ 1.5x normal diameter.
  • Patients with non-aneurysmal aortas who require aortic contrast imaging or echocardiography for preoperative planning or other reason.

Exclusion criteria

Exclusion Criteria:

  • Patients with to IV contrast such as allergy or severe kidney dysfunction.
  • Patients who do not require contrast imaging or echocardiogram as part of their care plan.
  • Terminally ill patients, and patients with estimated of ≤ 6 months.
  • Patients unable to tolerate magnetic resonance imaging.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Surveillance

    No Surgery with ECHO and ECG-gated MRA imaging.

    Device: ECHO · Device: ECG-gated MRA

  • Active comparator
    Surgery-Open

    Open Surgery with ECHO and ECG-gated MRA imaging.

    Device: ECHO · Device: ECG-gated MRA

  • Active comparator
    Surgery-EVAR

    EVAR with ECHO and ECG-gated MRA imaging.

    Device: ECHO · Device: ECG-gated MRA

Interventions

  • DeviceECHO

    Imaging

  • DeviceECG-gated MRA

    Imaging

06

What researchers measure

Primary outcomes

  1. ECHO Imaging

    Imaging taken of the aneurysm, locating peak wall stress and measuring percent of strain per seconds.

    Time frame: Change from baseline in ECHO imaging measurements

Secondary outcomes

  1. ECG-gated MRA Imaging

    The MRA imaging will be taken with the ECG-gating to synchronize the timing of the image acquisition with cardiac motion. This will allow for more accurate measurement of vessel diameter measured in mm (millimeters) and reported in percent change from baseline.

    Time frame: Change from baseline ECG-gated imaging measurements.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2015, a primary completion of Aug 2028 and a completion of Aug 2028. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2015
First posted
Sep 14, 2015
Start
Aug 2015
Primary completionEst.
Aug 2028
CompletionEst.
Aug 2028
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02548546
Lead sponsor
Mayo Clinic
Responsible party
Houssam Farres, M.D. (PI, Mayo Clinic) — Principal investigator
First posted
Sep 14, 2015
Start date
Aug 2015
Primary completion
Aug 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Sep 24, 2026

Study contacts

Houssam Farres, MD
Contact
farres.houssam@mayo.edu
904-953-2077
Mauricia Buchanan, RN
Contact
buchanan.mauricia@mayo.edu
904-953-2077
Houssam Farres, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion